Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Kratom Policy topic
No spam. Unsubscribe anytime.
Committee hears presentations and public comments on kratom prevalence and effects
Summary
DOJ and industry representatives presented on kratom's effects and presence in Montana; advocates and industry groups urged different regulatory approaches and committee members sought clarity on evidence and enforcement.
Steven Crawford, Narcotics Bureau Chief at the Montana Department of Justice, briefed the committee on 7‑hydroxymitragynine (kratom), describing observed effects, uses, and the substance’s presence in Montana. He presented Exhibit 23 as part of the briefing.
Public commenters representing the American Kratom Association (Scott Boulanger and Mac Haddow) and the Global Kratom Coalition (Walker Gallman) described user perspectives, potential benefits, and concerns about over‑regulation. Committee members including Sen. Sue Vinton and Rep. Steven Kelly asked panelists about evidence of harm, enforcement options, and regulatory tradeoffs.
Discussion focused on distinguishing epidemiological evidence from anecdotal reports and on what regulatory authority the state possesses. Staff and presenters agreed to provide follow‑up materials and clarifications for the committee to consider.
